Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Revenue projections:

Revenue projections for MDT
Revenue projections for MDT

MDT is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 2.535000
forwardPE 13.363525
debtToEquity 57.060000
earningsGrowth -0.118000
revenueGrowth 0.087000
grossMargins 0.651590
operatingMargins 0.200070
trailingEps 3.580000
forwardEps 6.059030

MDT's current ratio is 2.535, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting MDT has no trouble covering its short-term financial obligations.
Medtronic plc's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
Medtronic plc's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
With positive gross and operating margins, MDT demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
MDT's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting MDT to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for MDT
Price projections for MDT

The present price of Medtronic plc in relation to its projections indicates a lack of clear risks or opportunities. This balanced situation suggests that investors may find it prudent to wait for further signals before making significant moves in the stock.

Insider Transactions:

Insider Transactions for MDT
Insider Transactions for MDT


3 transactions to sell Medtronic plc occurred, with market price at 96.72333272298177.There were 1 buy transactions of Medtronic plc stock, with market price at 92.04000091552734 per share.Insider transactions fail to demonstrate any noticeable trend, leaving ambiguity about the company's potential trajectory or changes in its strategic approach.

Recommendation changes over time:

Recommendations trend for MDT
Recommendations trend for MDT


Analysts have shown a buy bias for MDT, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to MDT, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.